Reumatologia clinica最新文献

筛选
英文 中文
Changes in immature granulocyte levels and their association with disease activation following biologic therapy in patients with ankylosing spondylitis 强直性脊柱炎患者生物治疗后未成熟粒细胞水平的变化及其与疾病激活的关系
Reumatologia clinica Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.007
Burak Okyar , Servet Yüce , İbrahim Halil Bilen , Bekir Torun , İlyas Öztürk , Gözde Yıldırım Çetin
{"title":"Changes in immature granulocyte levels and their association with disease activation following biologic therapy in patients with ankylosing spondylitis","authors":"Burak Okyar ,&nbsp;Servet Yüce ,&nbsp;İbrahim Halil Bilen ,&nbsp;Bekir Torun ,&nbsp;İlyas Öztürk ,&nbsp;Gözde Yıldırım Çetin","doi":"10.1016/j.reumae.2024.11.007","DOIUrl":"10.1016/j.reumae.2024.11.007","url":null,"abstract":"<div><h3>Introduction</h3><div>AS is a chronic disease with an inflammatory serum microenvironment characterized by increased oxidative stress (OS). Along with OS, reactive oxygen species (ROS) are elevated in patients with AS. Overexpression of ROS causes active inflammatory processes leading to the secretion of pro-inflammatory factors, including tumor necrosis factor-alpha (TNF-α). Immature granulocytes (IG) are essential to the chronic inflammatory process. This may mean that IG can be a parameter used in the follow-up of chronic inflammatory diseases such as AS.</div></div><div><h3>Objective</h3><div>We aimed to evaluate the change in IG in patients with AS who were on biologic medication for six months after diagnosis and to assess its relationship with disease activity, remission, and BASDAI score.</div></div><div><h3>Methods</h3><div>This single-center, retrospective study was conducted between January 2020 and January 2022. For the study, 68 patients were included in the patient group and 74 patients in the control group. Demographic and laboratory data were recorded and compared in the groups. Then, the patient group was divided into two groups: pre-biologic drug and post-biologic drug. Hemogram data, IG, ESR, CRP, and BASDAI data were recorded for both groups. Correlation analysis was performed between the results of IG data and hemogram and laboratory data.</div></div><div><h3>Conclusion</h3><div>In our study, WBC, neutrophil, IG, and IG% ratios were significantly higher in AS patients compared to the control group. Neutrophil, IG, and IG% levels were significantly decreased in the AS group compared to pretreatment and post-treatment comparisons. In addition, IG levels were correlated with WBC, neutrophil, CRP, and ESR levels. This study hypothesized that IG values may be a valuable parameter for monitoring AS disease severity, response to treatment, and disease activation after biological drug use.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 533-538"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaccination against human papillomavirus in patients with immune-mediate diseases 为免疫性疾病患者接种人类乳头瘤病毒疫苗。
Reumatologia clinica Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.005
Marco Tobar-Marcillo , Carlos Guerrero-Solís , Daniel Goyes-Burbano , Jorge Esteban Toro-Tobar
{"title":"Vaccination against human papillomavirus in patients with immune-mediate diseases","authors":"Marco Tobar-Marcillo ,&nbsp;Carlos Guerrero-Solís ,&nbsp;Daniel Goyes-Burbano ,&nbsp;Jorge Esteban Toro-Tobar","doi":"10.1016/j.reumae.2024.11.005","DOIUrl":"10.1016/j.reumae.2024.11.005","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Page 570"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology of systemic lupus erythematosus in Latin America 拉丁美洲系统性红斑狼疮的流行病学。
Reumatologia clinica Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.003
Ivet Etchegaray-Morales , Claudia Mendoza-Pinto , Francisco Javier Arellano-Avendaño , Sandra Ibañez-Ovando , Pamela Munguía-Realpozo , Jacsiry Guadalupe Orbe-Sosa , Edith Ramírez-Lara , Mario García-Carrasco
{"title":"Epidemiology of systemic lupus erythematosus in Latin America","authors":"Ivet Etchegaray-Morales ,&nbsp;Claudia Mendoza-Pinto ,&nbsp;Francisco Javier Arellano-Avendaño ,&nbsp;Sandra Ibañez-Ovando ,&nbsp;Pamela Munguía-Realpozo ,&nbsp;Jacsiry Guadalupe Orbe-Sosa ,&nbsp;Edith Ramírez-Lara ,&nbsp;Mario García-Carrasco","doi":"10.1016/j.reumae.2024.11.003","DOIUrl":"10.1016/j.reumae.2024.11.003","url":null,"abstract":"<div><div>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects several organs, causing significant morbidity and increased mortality. It’s more frequent in young, fertile women and can appear in all ethnic groups.</div><div>The worldwide prevalence report indicates that there are at least 5 million patients with SLE. Although this disease can be found in every geographic region, certain races are more affected, such as Afro-American, Hispanic, and Asian populations. Furthermore, most of the epidemiologic information comes from Europe or the USA. In Latin America, only a few countries have reported data, like Argentina, Colombia, or Mexico, and even in these countries, the numbers vary.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 560-566"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of virtual reality in medical training: Clinical management of a patient with knee monoarthritis 虚拟现实在医学培训中的实用性:膝关节单关节炎患者的临床治疗。
Reumatologia clinica Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.004
Javier de Toro Santos , Ana Isabel Turrión , Mariano Andrés Collado , M. Carmen San José Méndez , Roberto Rilo Antelo , Juan Antonio Juanes Méndez
{"title":"Utility of virtual reality in medical training: Clinical management of a patient with knee monoarthritis","authors":"Javier de Toro Santos ,&nbsp;Ana Isabel Turrión ,&nbsp;Mariano Andrés Collado ,&nbsp;M. Carmen San José Méndez ,&nbsp;Roberto Rilo Antelo ,&nbsp;Juan Antonio Juanes Méndez","doi":"10.1016/j.reumae.2024.11.004","DOIUrl":"10.1016/j.reumae.2024.11.004","url":null,"abstract":"<div><div>The use of technological environments with virtual reality (VR) techniques for the practice of arthrocentesis offers an effective and safe way to learn and improve the necessary skills to carry out a medical procedure and patient care. This article presents an interactive simulator using immersive VR, in which the participant experiences practicing clinical management and decision-making in the face of a person presenting with monoarthritis in a medical consultation. The objective with this development is for the user to acquire the competence to perform, correctly and safely, a knee arthrocentesis and to differentiate the types of synovial fluids that can be found in a joint. In turn, it provides clinical guidance and assists with the user's medical decision-making. Therefore, the aim is to improve the quality of care and patient safety when practicing this technique previously through clinical simulation.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 555-559"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eosinophilic granulomatosis with poliangiitis: Successful treatment with methotrexate and low-dose of mepolizumab 嗜酸性肉芽肿伴脊髓灰质炎:使用甲氨蝶呤和小剂量甲泼尼珠单抗治疗获得成功
Reumatologia clinica Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.001
Luis Francisco Valdés-Corona , Patricia Aguilar-Dominguez , Ariel Jasqui-Bucay , Mariana Arroyo-Machiavelo
{"title":"Eosinophilic granulomatosis with poliangiitis: Successful treatment with methotrexate and low-dose of mepolizumab","authors":"Luis Francisco Valdés-Corona ,&nbsp;Patricia Aguilar-Dominguez ,&nbsp;Ariel Jasqui-Bucay ,&nbsp;Mariana Arroyo-Machiavelo","doi":"10.1016/j.reumae.2024.11.001","DOIUrl":"10.1016/j.reumae.2024.11.001","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 571-572"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychosis as a manifestation in systemic lupus erythematosus: treatment and long-term results. Number of cases 作为系统性红斑狼疮一种表现的精神病:治疗和长期效果。病例数。
Reumatologia clinica Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.002
Maria Joselin Rodarte-Gallegos, Ma. Azucena Ramos-Sánchez, Yadhira Mejia-Holguin, Ariana Maia Becerra-Márquez, Luciano Ortiz-Treviño
{"title":"Psychosis as a manifestation in systemic lupus erythematosus: treatment and long-term results. Number of cases","authors":"Maria Joselin Rodarte-Gallegos,&nbsp;Ma. Azucena Ramos-Sánchez,&nbsp;Yadhira Mejia-Holguin,&nbsp;Ariana Maia Becerra-Márquez,&nbsp;Luciano Ortiz-Treviño","doi":"10.1016/j.reumae.2024.11.002","DOIUrl":"10.1016/j.reumae.2024.11.002","url":null,"abstract":"<div><div>We present a case series of 5 patients with psychosis associated with SLE according to the ACR 1999 criteria. It presented as an initial clinical manifestation, clinically they had visual and auditory hallucinations, all the patients were women, average age 25 years, the accompanying manifestations were mostly mucocutaneous, articular and renal. Two patients presented antiphospholipid syndromes. The remission induction treatment was based on pulses of steroids and cyclophosphamide with a complete response in 4/5 patients, maintenance was left with mycophenolic acid and azathioprine.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 567-569"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical course and flare predictors in patients with rheumatoid arthritis in low disease activity and ultrasound remission monitored by ultrasound yearly and on-demand: A prospective 2-year observation study 低疾病活动性和超声缓解的类风湿性关节炎患者的临床病程和发作预测因素,每年和按需超声监测:一项前瞻性2年观察研究
Reumatologia clinica Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.08.001
Takeo Abe , Masao Tamura , Kazuyuki Tsuboi , Yuko Minagawa , Kazuteru Noguchi , Chie Ogita , Teppei Hashimoto , Naoto Azuma , Kiyoshi Matsui
{"title":"Clinical course and flare predictors in patients with rheumatoid arthritis in low disease activity and ultrasound remission monitored by ultrasound yearly and on-demand: A prospective 2-year observation study","authors":"Takeo Abe ,&nbsp;Masao Tamura ,&nbsp;Kazuyuki Tsuboi ,&nbsp;Yuko Minagawa ,&nbsp;Kazuteru Noguchi ,&nbsp;Chie Ogita ,&nbsp;Teppei Hashimoto ,&nbsp;Naoto Azuma ,&nbsp;Kiyoshi Matsui","doi":"10.1016/j.reumae.2024.08.001","DOIUrl":"10.1016/j.reumae.2024.08.001","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Ultrasound (US) remission in rheumatoid arthritis (RA) targets synovitis absence. Tenosynovitis triggers flares. Despite increased ultrasound use, flare patterns among patients with low disease activity (LDA) and ultrasound remission, especially in real-world settings, are poorly understood. This study examined flare rates and predictors of US remission in patients without synovitis or tenosynovitis.</div></div><div><h3>Materials and methods</h3><div>In a study of 88 patients achieving US remission and LDA, the focus was on the time to the first flare over a 2-year follow-up. US remission, indicated by the absence of active synovitis and tenosynovitis based on a power Doppler (US-PD) score of 0, was assessed on various joints. Flares are defined by the need for additional medication or encountering a US-PD flare. They were monitored at the baseline, 1-year, and 2-year visits with further US evaluation at clinical flare-ups. Baseline factors linked to a shorter time to flare were analyzed.</div></div><div><h3>Results</h3><div>At 1 year, LDA and US remission rates were 75% and 92%, respectively, and at 2 years, 73% and 87% respectively. Over the 2 years, 40% experienced flare, occurring on average at 11.7<!--> <!-->±<!--> <!-->7.0 months. Notably, 5.7% have US-PD flares without clinical signs. Analysis revealed Stage III disease and CRP as factors linked to a shorter time to flare.</div></div><div><h3>Discussion and conclusions</h3><div>In patients with RA achieving LDA and US remission, frequent flares were observed with US remission over 2 years, but most maintained sustained remission. Baseline factors are essential for predicting flares, emphasizing continuous monitoring and personalized treatment to sustain remission and minimize flare risks in RA management.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 517-525"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors associated with patient-reported outcome measures in knee osteoarthritis: A cross-sectional community-based study 与膝骨关节炎患者报告的结果测量相关的因素:一项基于社区的横断面研究
Reumatologia clinica Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.006
Rudy Hidayat , Faisal Parlindungan , Sumariyono Sumariyono , Suryo Anggoro Kusumo Wibowo , Anna Ariane , Johanda Damanik , Abirianty Priandani Araminta , Jessica Audrey , Mitra Alparisa
{"title":"Factors associated with patient-reported outcome measures in knee osteoarthritis: A cross-sectional community-based study","authors":"Rudy Hidayat ,&nbsp;Faisal Parlindungan ,&nbsp;Sumariyono Sumariyono ,&nbsp;Suryo Anggoro Kusumo Wibowo ,&nbsp;Anna Ariane ,&nbsp;Johanda Damanik ,&nbsp;Abirianty Priandani Araminta ,&nbsp;Jessica Audrey ,&nbsp;Mitra Alparisa","doi":"10.1016/j.reumae.2024.11.006","DOIUrl":"10.1016/j.reumae.2024.11.006","url":null,"abstract":"<div><h3>Introduction and objective</h3><div>Knee pain resulting from osteoarthritis (OA) often leads to functional limitations and disabilities, significantly affecting an individual's quality of life. This study aimed to explore the factors associated with patient-reported outcome measures in knee OA.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted using data from the Community Oriented Program for Control of Rheumatic Diseases (COPCORD) study in Jakarta. A home-to-home survey using multistage stratified random sampling was conducted involving subjects who met the clinical criteria for knee OA. Data collected included demographic information, body height and weight, history of injury, degree of work activities, presence of body aches and joint pain, and comorbidities. Patient-reported knee outcomes were assessed using the Knee Injury and Osteoarthritis Outcome Score (KOOS). Bivariate and multivariate analyses were performed to identify factors associated with KOOS and its subscales.</div></div><div><h3>Results</h3><div>A total of 71 subjects meeting the clinical criteria for knee OA were included in the analysis, with a mean age of 54.54<!--> <!-->±<!--> <!-->9.97 years. Cardiovascular disease was significantly associated with overall KOOS scores and all five subscales. Additionally, OA subjects with a history of knee injury scored worse specifically on the KOOS quality of life subscale.</div></div><div><h3>Conclusion</h3><div>Cardiovascular disease and a history of knee injury were significantly associated with worse patient-reported knee outcomes among knee OA subjects. Future studies involving more cities are recommended to confirm these findings and provide more robust results for the Indonesian population.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 526-532"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry tnf α-抑制剂在炎症性关节炎患者中作为第二种药物循环:来自多中心GO-REAL注册的数据
Reumatologia clinica Pub Date : 2024-12-01 DOI: 10.1016/j.reumae.2024.11.008
Carolina Ayelen Isnardi , Emma Estela Civit De Garignani , Agustín García Ciccarelli , Jimena Sanchez Alcover , Ingrid Strusberg , Marcos Baravalle , Sol Castaños , Liliana Morales , Matias Palombo , Eduardo Albiero , Carla Gobbi , Rodrigo Garcia Salinas , Sebastian Magri , Edson Velozo , Enrique R. Soriano , Alfredo Vargas Caselles , Luis Carlos Palomino Romero , Sergio Paira , Romina Calvo , Alberto Ortiz , Gustavo Citera
{"title":"TNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry","authors":"Carolina Ayelen Isnardi ,&nbsp;Emma Estela Civit De Garignani ,&nbsp;Agustín García Ciccarelli ,&nbsp;Jimena Sanchez Alcover ,&nbsp;Ingrid Strusberg ,&nbsp;Marcos Baravalle ,&nbsp;Sol Castaños ,&nbsp;Liliana Morales ,&nbsp;Matias Palombo ,&nbsp;Eduardo Albiero ,&nbsp;Carla Gobbi ,&nbsp;Rodrigo Garcia Salinas ,&nbsp;Sebastian Magri ,&nbsp;Edson Velozo ,&nbsp;Enrique R. Soriano ,&nbsp;Alfredo Vargas Caselles ,&nbsp;Luis Carlos Palomino Romero ,&nbsp;Sergio Paira ,&nbsp;Romina Calvo ,&nbsp;Alberto Ortiz ,&nbsp;Gustavo Citera","doi":"10.1016/j.reumae.2024.11.008","DOIUrl":"10.1016/j.reumae.2024.11.008","url":null,"abstract":"<div><h3>Introduction/Objectives</h3><div>There are still controversies about the efficacy of cycling to a second tumor necrosis factor inhibitor (TNFi) in patients with inflammatory arthritis. The aim of this study was to evaluate survival, persistence and effectiveness of golimumab (GLM) in patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) with previous experience with other TNFi and to compare these results with TNFi naive patients.</div></div><div><h3>Methods</h3><div>Observational cohort of consecutive patients with RA, PsA and axSpA who had started treatment with GLM according to medical indication. bDMARD naive and TNFi experienced patients were selected.</div></div><div><h3>Results</h3><div>A total of 147 (62.3%) bDMARD naive and 45 (19.1%) TNFi experienced patients were included. Patients were followed up for a total of 441.5 patients/year, 55 (28.6%) discontinued GLM, 42 (28.6%) and 13 (28.9%) in each group, respectively (<em>p</em> <!-->=<!--> <!-->0.967). The majority (63.6%) suspended due to inefficacy, followed by lack of access (23.6%) and adverse events (9.1%). Median GLM survival was 74.0 months (95% CI 57.0, 91.0) and 71.0 months (95% CI 37.0, 105.0), in the bDMARD naive and TNFi experienced patients, respectively (<em>p</em> <!-->=<!--> <!-->0.695). Drug persistence at 6, 12, 24 and 36 months was 92.8%, 88.1%, 76.1%, 65.4% and 93.1%, 77.4%, 74.2%, 68.5%, respectively. In the multivariable analysis, having public health insurance was associated with higher risk of drug discontinuation (HR 2.56, 95% CI 1.28–5.00, <em>p</em> <!-->=<!--> <!-->0.008). TNFi experienced patients did not show significantly higher risk of GLM suspension (HR 1.35, 95% CI 0.70–2.57, <em>p</em> <!-->=<!--> <!-->0.370).</div></div><div><h3>Conclusion</h3><div>In this cohort, TNFi experienced patients had comparable survival and persistence of treatment with GLM. Having public health insurance was associated with lower drug retention rates.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 10","pages":"Pages 539-546"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HLA-B*51:01 in Iranian patients with Behcet uveitis syndrome 伊朗白塞氏葡萄膜炎综合征患者的 HLA-B*51:01。
Reumatologia clinica Pub Date : 2024-11-01 DOI: 10.1016/j.reumae.2024.07.011
Zahra Hoseini , Fatemeh Rezaei Rad , Mohammad Zarei , Nazanin Ebrahimiadib , Zahra Salimian , Mahdi Zamani
{"title":"HLA-B*51:01 in Iranian patients with Behcet uveitis syndrome","authors":"Zahra Hoseini ,&nbsp;Fatemeh Rezaei Rad ,&nbsp;Mohammad Zarei ,&nbsp;Nazanin Ebrahimiadib ,&nbsp;Zahra Salimian ,&nbsp;Mahdi Zamani","doi":"10.1016/j.reumae.2024.07.011","DOIUrl":"10.1016/j.reumae.2024.07.011","url":null,"abstract":"<div><h3>Background</h3><div>Behcet's disease (BD) is a multisystem disorder prevalent along the historic Silk Road, with Behcet's uveitis (BU) representing a significant complication contributing to disability. Various studies have linked different HLA alleles with BD across diverse populations.</div></div><div><h3>Methods</h3><div>In this study, we investigated the association between HLA-B51:01/x and HLA-B27/x genotypes with Behcet's uveitis in 50 unrelated Iranian patients diagnosed with Behcet's uveitis, comparing them to a control group of 70 healthy individuals. Our analysis aimed to determine the susceptibility conferred by these alleles and assess their clinical relevance.</div></div><div><h3>Results</h3><div>Our findings indicate a notable susceptibility conferred by the HLA-B51:01/x genotype for Behcet's uveitis (<em>P</em> <!-->=<!--> <!-->0.0001). Conversely, the B27/x genotype did not demonstrate significant associations with Behcet's uveitis. Furthermore, we employed prevalence-corrected positive predictive value (PcPPV) calculations to gauge the clinical utility of testing for these alleles within the Iranian Behcet's uveitis patient population. The PcPPV for B27/x genotype testing was determined to be 0.05%, while the PcPPV for B51:01/x genotype testing in the same population was 0.065%. These results suggest that carriers of the B*51:01 allele, when presenting with clinical symptoms, exhibit a heightened risk for Behcet's uveitis compared to the general population.</div></div><div><h3>Conclusion</h3><div>Individuals carrying the B51:01 allele, when symptomatic, face an elevated Behcet's uveitis risk. This insight aids in targeted clinical assessments for at-risk populations.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 9","pages":"Pages 470-475"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信